Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

• Conditions: Glioblastoma; Squamous Cell Carcinoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma; Breast Cancer; Prostate Cancer; Gastric Cancer; Ovarian Cancer; Acute Leukemia; Pancreatic Cancer

• Registration Number: NCT05974410
• Lead Sponsor: AVM Biotechnology Inc

Brief Summary

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-07-26
• Study First Submitted QC: 2023-07-26
• Study First Posted: 2023-08-03
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-29
• Last Update Posted: 2025-10-02

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-

Exclusion Criteria

-

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified